The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Vadimezan     2-(5,6-dimethyl-9-oxo- xanthen-4...

Synonyms: DMXAA, vadimezanum, PubChem22437, ASA-404, CHEMBL71263, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dimethyloxoxanthene acetic acid


High impact information on Dimethyloxoxanthene acetic acid


Chemical compound and disease context of Dimethyloxoxanthene acetic acid


Biological context of Dimethyloxoxanthene acetic acid


Anatomical context of Dimethyloxoxanthene acetic acid


Associations of Dimethyloxoxanthene acetic acid with other chemical compounds


Gene context of Dimethyloxoxanthene acetic acid


Analytical, diagnostic and therapeutic context of Dimethyloxoxanthene acetic acid


  1. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Siim, B.G., Laux, W.T., Rutland, M.D., Palmer, B.N., Wilson, W.R. Cancer Res. (2000) [Pubmed]
  2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Jassar, A.S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M.B., Cheung, L., Burdick, M.D., Strieter, R.M., Ching, L.M., Kaiser, L.R., Albelda, S.M. Cancer Res. (2005) [Pubmed]
  3. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Zhao, L., Ching, L.M., Kestell, P., Baguley, B.C. Br. J. Cancer (2002) [Pubmed]
  4. DMXAA: an antivascular agent with multiple host responses. Baguley, B.C., Ching, L.M. Int. J. Radiat. Oncol. Biol. Phys. (2002) [Pubmed]
  5. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. Beauregard, D.A., Pedley, R.B., Hill, S.A., Brindle, K.M. NMR in biomedicine. (2002) [Pubmed]
  6. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Bellnier, D.A., Gollnick, S.O., Camacho, S.H., Greco, W.R., Cheney, R.T. Cancer Res. (2003) [Pubmed]
  7. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. Galbraith, S.M., Rustin, G.J., Lodge, M.A., Taylor, N.J., Stirling, J.J., Jameson, M., Thompson, P., Hough, D., Gumbrell, L., Padhani, A.R. J. Clin. Oncol. (2002) [Pubmed]
  8. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar, J.R., Kanwar, R.K., Pandey, S., Ching, L.M., Krissansen, G.W. Cancer Res. (2001) [Pubmed]
  9. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Joseph, W.R., Cao, Z., Mountjoy, K.G., Marshall, E.S., Baguley, B.C., Ching, L.M. Cancer Res. (1999) [Pubmed]
  10. Thalidomide in cancer treatment: a potential role in the elderly? Zhou, S., Kestell, P., Tingle, M.D., Paxton, J.W. Drugs & aging. (2002) [Pubmed]
  11. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Zhao, L., Ching, L.M., Kestell, P., Kelland, L.R., Baguley, B.C. Int. J. Cancer (2005) [Pubmed]
  12. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Ching, L.M., Cao, Z., Kieda, C., Zwain, S., Jameson, M.B., Baguley, B.C. Br. J. Cancer (2002) [Pubmed]
  13. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Zhou, S., Kestell, P., Paxton, J.W. Drug Metab. Rev. (2002) [Pubmed]
  14. Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Ching, L.M., Joseph, W.R., Baguley, B.C. Biochem. Pharmacol. (1992) [Pubmed]
  15. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Ching, L.M., Young, H.A., Eberly, K., Yu, C.R. Biochem. Pharmacol. (1999) [Pubmed]
  16. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Moilanen, E., Thomsen, L.L., Miles, D.W., Happerfield, D.W., Knowles, R.G., Moncada, S. Br. J. Cancer (1998) [Pubmed]
  17. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Ching, L.M., Joseph, W.R., Crosier, K.E., Baguley, B.C. Cancer Res. (1994) [Pubmed]
  18. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Ching, L.M., Goldsmith, D., Joseph, W.R., Körner, H., Sedgwick, J.D., Baguley, B.C. Cancer Res. (1999) [Pubmed]
  19. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Zhao, L., Kestell, P., Philpott, M., Ching, L.M., Zhuang, L., Baguley, B.C. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  20. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Webster, L.K., Ellis, A.G., Kestell, P., Rewcastle, G.W. Drug Metab. Dispos. (1995) [Pubmed]
  21. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Murata, R., Overgaard, J., Horsman, M.R. Int. J. Radiat. Biol. (2001) [Pubmed]
  22. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Pili, R., Rosenthal, M.A., Mainwaring, P.N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S., Clingan, P. Clin. Cancer Res. (2010) [Pubmed]
  23. 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. Zhou, S., Kestell, P., Paxton, J.W. European journal of drug metabolism and pharmacokinetics. (2002) [Pubmed]
  24. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Zhou, S., Kestell, P., Baguley, B.C., Paxton, J.W. Biochem. Pharmacol. (2003) [Pubmed]
  25. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Woon, S.T., Zwain, S., Schooltink, M.A., Newth, A.L., Baguley, B.C., Ching, L.M. Eur. J. Cancer (2003) [Pubmed]
  26. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Pedley, R.B., Sharma, S.K., Boxer, G.M., Boden, R., Stribbling, S.M., Davies, L., Springer, C.J., Begent, R.H. Cancer Res. (1999) [Pubmed]
  27. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. Perera, P.Y., Barber, S.A., Ching, L.M., Vogel, S.N. J. Immunol. (1994) [Pubmed]
  28. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Siim, B.G., Lee, A.E., Shalal-Zwain, S., Pruijn, F.B., McKeage, M.J., Wilson, W.R. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  29. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Zhao, L., Kestell, P., Ching, L.M., Baguley, B.C. Cancer Chemother. Pharmacol. (2002) [Pubmed]
WikiGenes - Universities